Heron Therapeutics (HRTX) Payables: 2010-2025
Historic Payables for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $12.0 million.
- Heron Therapeutics' Payables rose 17.95% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $197.9 million, marking a year-over-year increase of 708.06%. This contributed to the annual value of $11.7 million for FY2024, which is 261.39% up from last year.
- Heron Therapeutics' Payables amounted to $12.0 million in Q3 2025, which was down 92.57% from $161.8 million recorded in Q2 2025.
- In the past 5 years, Heron Therapeutics' Payables registered a high of $161.8 million during Q2 2025, and its lowest value of $837,000 during Q1 2024.
- In the last 3 years, Heron Therapeutics' Payables had a median value of $10.2 million in 2024 and averaged $20.9 million.
- In the last 5 years, Heron Therapeutics' Payables plummeted by 85.82% in 2023 and then surged by 1,482.66% in 2025.
- Over the past 5 years, Heron Therapeutics' Payables (Quarterly) stood at $3.8 million in 2021, then declined by 15.20% to $3.2 million in 2022, then climbed by 0.47% to $3.2 million in 2023, then soared by 261.39% to $11.7 million in 2024, then climbed by 17.95% to $12.0 million in 2025.
- Its Payables was $12.0 million in Q3 2025, compared to $161.8 million in Q2 2025 and $12.3 million in Q1 2025.